Financial and Risk Analysis of Kontour Medical

Authors

  • Yuchen Zhu

DOI:

https://doi.org/10.54097/2ymcaq05

Keywords:

Financial analysis, Risk, Kontour Medical

Abstract

Orthopedic medical devices are one of the largest sub industries in the medical device industry, and orthopedic implants are the most important category of orthopedic devices, usually devices and materials that are partially or completely implanted in the human body after surgery or surgery to replace, support, locate, or repair tissues such as bones, joints, and cartilage. This article introduces situation of medical device industry and Kontour Medical Co., LTD (Kontour Medical). By analyzing the key financial data of Kontour Medical and comparing the data with other similar medical device companies, including the income statement, balance sheet. In addition, the profitability, liquidity, solvency and operating performance of the Kontour Medical were analyzed. This paper evaluated the performance and the value of Kontour Medical. According to the dynamic change of the medical device industry, it also has given some comments and suggestions to the investors, especially about the government centralized procurements.

Downloads

Download data is not yet available.

References

Wang, J. (2022). Factor Analysis for Financial Performance Evaluation of Listed Chinese Medicine Companies. Mobile Information Systems, 2022.

Wang, H. (2021, February). Research on High-Value Medical Consumables and Related Companies in China. In 6th International Conference on Economics, Management, Law and Education (EMLE 2020) (pp. 310-314). Atlantis Press.

Daryanto, C., & Daryanto, W. M. (2019). Financial performance analysis and evaluation of pharmaceutical companies in Indonesia. International Journal of Innovation, Creativity and Change, 6 (3), 207-224.

Masanga, G. G., Munyoro, G., & Mugwagwa, P. F. (2017). An evaluation of business models in the private healthcare services sector in Zimbabwe: A case study of three healthcare companies in Harare. International Journal of Research in Business Management, 5 (5), 117-136.

Nie, P. (2022). Research on Financial Risk Early Warning of H Medicine Company Based on Efficacy Coefficient Method. In 2022 5th International Conference on Interdisciplinary Social Sciences & Humanities.

Michaeli, D. T., Yagmur, H. B., Achmadeev, T., & Michaeli, T. (2022). Valuation and returns of drug development companies: lessons for bioentrepreneurs and investors. Therapeutic Innovation & Regulatory Science, 56 (2), 313-322.

Yang, R., & Jiang, Q. (2020). Detecting Falsified Financial Statements Using a Hybrid SM-UTADIS Approach: Empirical Analysis of Listed Traditional Chinese Medicine Companies in China. Discrete Dynamics in Nature and Society, 2020, 1-15.

Alali, E., Alhammadi, N., Almarar, M. S., Almheiri, S., Almarar, F., Almarar, M., ... & Nobanee, H. (2021). Financial Analysis and Performance Evaluation of Moderna. Available at SSRN 3896199.

Chen, Z. (2022). Financial Analysis and Valuation Study of Chinese Listed Companies: The Case of “Tongce” Medical. Journal of Economics, Finance and Accounting Studies, 4 (2), 324-331.

Murayama, A., Saito, H., & Murayama, A. (2023). Assessment of Financial Relationships between Otorhinolaryngologists and Pharmaceutical Companies in Japan between 2016 and 2019.

Downloads

Published

22-01-2024